Landfar(SZ:000504) Xin Lang Cai Jing·2026-01-23 02:38Core Viewpoint - *ST Bio is facing significant challenges, including delisting risks, performance volatility, and uncertainties surrounding its restructuring efforts, leading to a sharp decline in stock price and investor confidence [2]. Group 1: Company Fundamentals - *ST Bio's stock hit the limit down price of 8.84 yuan, with a decline of 4.95%, resulting in a total market capitalization of 29.17 billion yuan and a circulating market value of 29.09 billion yuan [1]. - The company is undergoing a critical phase of business transformation and financial restructuring, with expected profitability and substantial revenue growth in 2025, but 2024 financial indicators trigger delisting risk warnings [2]. - The company is projected to incur a net loss in 2024, with significant performance fluctuations and a high proportion of non-recurring gains, alongside rising debt levels, which are undermining market confidence [2]. Group 2: Restructuring and Market Sentiment - The major asset restructuring is currently in the planning stage, with uncertainties regarding its implementation, leading to skepticism about the restructuring's effectiveness and negatively impacting investor confidence [2]. - The newly introduced "yesterday's limit-up" concept lacks sustainability and fails to have a substantial impact on the company's fundamentals, which does not support the stock price [2]. - The competitive landscape in the biopharmaceutical industry poses risks for the company's business integration, and the performance contribution from the newly acquired Jin Hong New Materials remains to be observed [2]. Group 3: Technical and Financial Aspects - Due to the numerous uncertainties faced by the company, there may be a potential outflow of funds, which could lead to technical indicators such as MACD crossovers and BOLL channel breakdowns, further exacerbating stock price declines [2].